More than 40,000 allogeneic hematopoietic stem cell transplants are carried out worldwide every year, mostly for patients suffering from leukemia or other diseases of the hematopoietic system. Very often, the so-called graft-versus-host reaction occurs, an inflammatory disease that can affect different organs and is caused by an unwanted defense reaction of the donor cells and the body’s own T cells. Scientists at CeMM, Medical University of Vienna and LBI-RUD, led by Georg Stary, now show how these endogenous, tissue-derived T cells enter other organs, such as the intestine, via the blood and contribute to inflammation there. The study…Read more
First worldwide personalized-medicine study using a functional test demonstrates clinical feasibility and efficacy of individualized therapy in leukemia and lymphoma patients
Standard therapy for advanced recurring aggressive, hematological malignancies, such as leukemias and lymphomas, have a limited effect with patients experiencing short survival times. A study at the Vienna General Hospital conducted by physicians and scientists from Medical University Vienna and CeMM, as well as ETH Zurich for the first time demonstrated that therapy selection based on results from a functional test is clinically possible and effective in patients with recurrent hematologic cancers. The researchers quantified drug effects on single cells from real-time patient biopsies using a novel experimental technique, resulting in 56…Read more
RESOLUTE is a public-private partnership with 13 partners from academia and industry with an overarching goal: To trigger an escalation in the appreciation and intensity of research on solute carriers (SLCs) worldwide and to establish SLCs as a tractable target class for medical research and development. The project is coordinated by CeMM and Pfizer.
From 4th to 7th October 2021, Novartis and Vifor Pharma hosted the 6th RESOLUTE Consortium Meeting in Basel (Switzerland) and virtually. Around 100 participants joined the hybrid event and discussed their projects and publication strategies.
Participants were welcomed at the Novartis campus and…Read more
Cachexia is the name of a syndrome that is associated with numerous chronic diseases. It refers to weight loss induced by shrinkage of both fat reserves and muscle tissue. Although the occurrence of cachexia can have serious implications on patients’ health and survival, there are many aspects of this syndrome that are unknown and therapeutic options remain very limited. Scientists from Andreas Bergthaler's research group at CeMM emphasize the need for more research into cachexia in their recent publication in Nature Reviews Immunology. In order to counteract cachexia and numerous other diseases, a better understanding of the interplay…Read more
As a pioneering institute with the goal of achieving maximum scientific innovation in molecular medicine to improve healthcare, CeMM is fully committed to identifying, supporting, and developing its research discoveries into impactful solutions for society. In line with this, once again this year on 25-28 October, CeMM will be joining the BIO-Europe Digital conference, the meeting point for global biopharma and investment leaders to build partnerships that facilitate innovation and medical breakthroughs.
CeMM IP and Technology Transfer Manager, Prudence Donovan, together with the heads of CeMM services and facilities, Christoph Bock,…Read more
Eco-friendly process for synthesizing organic materials developed for high-performance materials industry
Until now, the production of materials from organic substances was only possible with the use of highly toxic solvents. A team led by chemist Miriam Unterlass, Professor at the University of Konstanz and Adjunct Principal Investigator at CeMM, has now developed a method for making organic substances suitable for use as high-performance materials in an eco-friendly and completely non-toxic way by generating them in only hot water. The study represents an important milestone in the green production of organic materials and thus also provides an important incentive to switch from inorganic to organic, renewable materials. Beside that the method…Read more
On 6 September 2021, schoolteacher Alexandra Schmidl joins CeMM as part of the Seitenwechsel program, which fosters fruitful exchanges among companies and teachers in Austria. During the next year, she will have a full immersion in the scientific environment at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, where she will benefit from daily interactions with CeMM researchers. The knowledge and new techniques that she acquires, will be then applied in her teaching when she goes back to her classroom next year. CeMM will not only profit from her everyday school life know-how, but will also gain further…Read more
Congratulations to Kaan Boztug, Scientific Director of the St. Anna Children's Cancer Research Institute, Director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases and CeMM Adjunct Principal Investigator, who has been awarded the Işil Berat Barlan Award for his outstanding research in the field of primary immunodeficiencies, which will be presented for the first time this year at the European Congress of Immunology (ECI).
The scientist receives this award for his pioneering research on immunodeficiencies. Disturbances in the balance of the immune system can be the starting point for a number of diseases such as increased…Read more
Robert Kralovics has been associated with CeMM for 15 years, being one of the very first internationally recruited Principal Investigators to join our institute. On 31 August 2021, his CeMM affiliation comes to an end, and therefore we would like to thank him greatly for all his scientific contributions and personal engagement with CeMM and our community.
Robert earned his master’s degree in Molecular Biology and Genetics at Comenius University and his PhD in Genomics at the Institute of Biophysics of the Academy of Sciences of the Czech Republic. His postdoctoral work was based on the genetics of myeloproliferative disorders working with…Read more
CeMM receives “Innovation Award 2021/2022” for Inorganic Chemistry and is one of the most innovative companies in Vienna
For the second time, CeMM wins the Innovation Award of the ÖGVS – Gesellschaft für Verbraucherstudien (Society for Consumer Studies). Measured by the number of patents granted worldwide and supplemented by the qualitative moment of citation frequency, CeMM ranks in the top group of the main class Inorganic Chemistry as well as in the top 10% of the most innovative companies and research institutions in Vienna.
At CeMM internationally recognized cutting-edge research is conducted in the field of molecular medicine. CeMM integrates basic research and clinical expertise to develop innovative diagnostic and therapeutic approaches to improve…Read more